Lrrk2 (Leucine Rich Repeat Kinase 2) is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin (from the Basque word dardara, meaning "tremor"), is a large multidomain protein encoded by the LRRK2 gene (PARK8 locus) on chromosome 12q12. [LRRK2 is both a GTPase and a kinase, making it a unique dual protein. Mutations in LRRK2 represent the most common genetic cause of [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, accounting for 1–2% of all PD cases and up to 40% of familial PD in certain populations (e.g., North African Arab Berbers and Ashkenazi Jews) 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC10270275/) (Li X et al., 2025).
LRRK2 has emerged as one of the most promising therapeutic targets in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, with several kinase inhibitors and [antisense oligonucleotides[/technologies/[antisense-oligonucleotides[/technologies/[antisense-oligonucleotides[/technologies/[antisense-oligonucleotides--TEMP--/technologies)--FIX-- in clinical development. Its role in vesicular trafficking, [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX--, lysosomal function, and immune signaling places it at the intersection of multiple pathological pathways implicated in neurodegeneration (Boecker CA et al., 2021).
The LRRK2 gene spans approximately 144 kb of genomic DNA and contains 51 exons. It encodes a 2527-amino acid protein (~286 kDa), making LRRK2 one of the largest protein kinases in the human genome 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC11466701/).
LRRK2 contains multiple functional domains arranged from N-terminus to C-terminus:
The ROC-COR-Kinase enzymatic core is unique to LRRK2, with the GTPase and kinase activities being functionally interdependent. GTP binding to the ROC domain activates the kinase domain, while kinase activity may influence GTPase function.
LRRK2 is expressed in multiple tissues, with highest levels in the kidneys, lungs, and immune cells (monocytes, macrophages, B cells). In the brain, LRRK2 is expressed in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--], and [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- | 2–3× increased kinase activity |
| R1441C/G/H | ROC (GTPase) | Second most common | Reduced GTPase activity |
| Y1699C | COR | Rare | Impaired dimerization |
| I2020T | Kinase | Rare (Japanese families) | Modestly increased kinase activity |
| N1437H | ROC | Rare | Reduced GTPase activity |
The G2019S mutation is located in the activation loop of the kinase domain (DYG motif → DYS) and directly enhances kinase activity 2–3-fold. It is present in approximately 1% of sporadic PD cases and up to 4% of familial PD globally 4(https://pubmed.ncbi.nlm.nih.gov/37021623/).
LRRK2 mutations show age-dependent, incomplete penetrance. The penetrance of G2019S is estimated at:
This incomplete penetrance suggests that additional genetic and environmental factors modify disease risk, offering a potential window for preventive intervention 1(https://pmc.ncbi.nlm.nih.gov/articles/PMC10270275/).
Unlike most forms of PD, LRRK2-associated PD shows remarkable neuropathological variability:
This heterogeneity suggests that LRRK2 mutations trigger neurodegeneration through mechanisms upstream of [protein aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX--.
A major breakthrough in LRRK2 biology was the identification of Rab GTPases as bona fide LRRK2 substrates. LRRK2 phosphorylates a subset of Rab proteins, including Rab3A/B/C/D, Rab8A/B, Rab10, Rab12, Rab29 (Rab7L1), and Rab35, at conserved threonine/serine residues in their switch II effector domain 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC7095371/) (Eguchi T et al., 2018).
Phosphorylation of Rabs by LRRK2:
Pathogenic LRRK2 mutations increase Rab phosphorylation, and phospho-Rab10 and phospho-Rab12 levels in blood and CSF are being explored as pharmacodynamic biomarkers for LRRK2 inhibitor [clinical trials/clinical-trials).
LRRK2 is a key regulator of the autophagy-lysosomal pathway:
LRRK2 regulates multiple aspects of vesicular trafficking:
LRRK2 localizes to the outer [mitochondrial membrane] and interacts with mitochondrial fission/fusion machinery:
LRRK2 is highly expressed in immune cells and plays significant roles in [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--:
LRRK2 kinase activity promotes the propagation of [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--/proteins/alpha transmission between [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- 9(https://www.sciencedirect.com/science/article/pii/S000989812100276X) (Madureira et al., 2020).
Since pathogenic mutations increase LRRK2 kinase activity, kinase inhibitors are the leading therapeutic strategy:
Type I Inhibitors (target active conformation):
Type II Inhibitors (target inactive conformation):
A key safety concern with LRRK2 inhibitors is the "lung phenotype": LRRK2 kinase inhibition in preclinical models causes type II pneumocyte accumulation of lamellar bodies, resembling lysosomal storage. Clinical monitoring of lung function is included in all ongoing trials 11(https://pmc.ncbi.nlm.nih.gov/articles/PMC12235878/).
BIIB094, an antisense oligonucleotide designed to reduce LRRK2 protein levels, was tested in the Phase I REASON trial. However, Biogen discontinued its development in early 2025 11(https://pmc.ncbi.nlm.nih.gov/articles/PMC12235878/).
Beyond rare pathogenic mutations, common variants at the LRRK2 locus are associated with increased risk for sporadic PD in genome-wide association studies. Protective variants (e.g., N551K-R1398H) that reduce LRRK2 kinase activity have also been identified, further supporting LRRK2 kinase inhibition as a therapeutic strategy 12(https://link.springer.com/article/10.1007/s40263-026-01275-y).
The study of Lrrk2 (Leucine Rich Repeat Kinase 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.